LIVZON PHARMAC. GRP H YC1 Total Liabilities
LIVZON PHARMAC. GRP H YC1 total liabilities. Based on the latest financial reports, LIVZON PHARMAC. GRP H YC1 (LP6) has total liabilities worth €8.61 Billion EUR (≈ $10.07 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LP6 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of LIVZON PHARMAC. GRP H YC1 (2021–2025)
Total liabilities of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. This chart illustrates how LIVZON PHARMAC. GRP H YC1's total liabilities have evolved over time, based on quarterly financial data.
LIVZON PHARMAC. GRP H YC1 Competitors by Total Liabilities
The table below lists competitors of LIVZON PHARMAC. GRP H YC1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ZKTECO Co. Ltd. A
SHE:301330
|
China | CN¥1.29 Billion |
|
CNB Financial Corporation
NASDAQ:CCNE
|
USA | $7.52 Billion |
|
N-Able Inc
NYSE:NABL
|
USA | $596.49 Million |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥442.16 Million |
|
Joeone Co Ltd
SHG:601566
|
China | CN¥1.61 Billion |
|
Jaya Real Property Tbk
JK:JRPT
|
Indonesia | Rp4.48 Trillion |
|
Quechen Silicon Chemical Co. Ltd.
SHG:605183
|
China | CN¥578.50 Million |
|
Guangxi Radio and Television Information Network Corp Ltd
SHG:600936
|
China | CN¥3.49 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down LIVZON PHARMAC. GRP H YC1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LP6 asset base.
Liquidity & Leverage Metrics
LIVZON PHARMAC. GRP H YC1 Total Liabilities Ratios Explained
LIVZON PHARMAC. GRP H YC1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LIVZON PHARMAC. GRP H YC1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LIVZON PHARMAC. GRP H YC1 (2021–2025)
The table below shows the annual total liabilities of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €8.44 Billion ≈ $9.87 Billion |
-11.64% |
| 2024-12-31 | €9.55 Billion ≈ $11.17 Billion |
-7.08% |
| 2023-12-31 | €10.28 Billion ≈ $12.02 Billion |
+3.49% |
| 2022-12-31 | €9.93 Billion ≈ $11.61 Billion |
+23.21% |
| 2021-12-31 | €8.06 Billion ≈ $9.42 Billion |
-- |
About LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more